Disc Medicine announced its Q1 2026 financial results, highlighting the completion of enrollment for its Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP), with topline data expected in Q4 2026. The company also plans to present updated Phase 2 data for DISC-0974 in myelofibrosis anemia at the ASCO meeting and expects data from ongoing studies of DISC-3405 in polycythemia vera and sickle cell disease by Q4 2026. Disc Medicine ended Q1 with $730 million in cash, supporting operations into 2029. These milestones position the company for multiple important catalysts later this year.
Cortea secured €12 million in funding led by Dawn Capital to develop AI-powered Audit Quality Agents that review audit reports and financial statements, identifying errors and inconsistencies before sign-off. These tools help audit firms improve qual...
Cortea secured €12 million in seed funding led by Dawn Capital to develop AI tools that enhance audit quality without compromising accuracy. Their Audit Quality Agents review audit reports and financial statements to detect inconsistencies and errors...
Hong Kong Tourism Board has launched the "Hong Kong Summer Fun" campaign featuring a series of vibrant summer events including the 50th Sun Life Hong Kong International Dragon Boat Festival, Pixar Summer Fest, and a major football event with top Euro...
Hong Kong Tourism Board has launched the "Hong Kong Summer Fun" campaign, featuring festivals, family attractions, sports events, and exclusive summer deals valid until August 31. Highlights include the 50th Sun Life Hong Kong International Dragon Bo...
XTransfer has been recognized for the second consecutive year in FXC Intelligence’s 2026 Top 100 Cross-Border Payments Companies list, highlighting its role in advancing global B2B payment solutions. The company, serving over 890,000 enterprises in 2...
